The story of the vaccine roll-out has dominated the first half of this year. The drama proceeded on two fronts in Britain: we delighted in the raw number of jabs in arms – at its peak, hitting 500,000 per day – and found solace in the rapid vaccination of close social networks.
After a family Zoom in March, I reflected that everyone on the call (bar me) had had at least one shot. It’s my turn next week. It’s the culmination of a remarkable story reflecting the strength of the biomedical sciences across the West and a symbiosis between innovative minnows (none of the leading vaccines were developed by the ‘big beasts’ in the vaccine field like GSK) and bigger fish.